Samsung’s Galaxy Buds win FDA clearance as over-the-counter hearing aids

More than 1.5 billion people worldwide live with some degree of hearing loss, yet most never use a hearing aid. The reasons are familiar: cost, stigma, and the inconvenience of clinical appointments. Samsung has now cleared a significant regulatory hurdle that could change that calculation, at least for those with mild to moderate hearing loss.

Samsung Electronics announced on August 11, 2026, that its Galaxy Buds Hearing Aid feature has received clearance from the U.S. Food and Drug Administration. The feature turns compatible Galaxy Buds into over-the-counter hearing aids, available without a prescription or a visit to an audiologist, for users aged 18 and older.

The announcement is notable not just because of the FDA stamp of approval, but because of what it signals about the direction of consumer health technology. Earphones are already ubiquitous. Turning them into clinically validated medical devices brings hearing support into a category that hundreds of millions of people already own and wear daily.

How does it work?

The hearing health experience is built around two features, both integrated directly into the Galaxy Buds settings without needing a separate app.

• Hearing Test: A five-minute, self-administered test using clinical-grade pure-tone audiometry. It tests each ear individually and generates an audiogram, classifying hearing as normal or at one of four stages of loss: mild, moderate, severe, or profound. The feature is registered as a Software as a Medical Device (SaMD).
• Hearing Aid: Based on the test results, the feature amplifies specific sounds the user struggles to hear, including high frequencies, whispers, and distant voices. It also includes noise elimination and beamforming technology, which focuses sound from in front of the user and suppresses background noise.

Both features use the NAL-NL2 formula, the globally recognised clinical standard for fitting prescription hearing aids. Samsung developed the technology in collaboration with the National Acoustic Laboratories and Samsung Medical Center, with clinical validation studies conducted at Vanderbilt University Medical Center, San Jose State University, and the University of Memphis. Hearing-related data, including noise exposure levels and test results, feeds into the Samsung Health app for a broader view of the user's wellness.

Why does it matter?

The World Health Organization projects that 2.5 billion people will experience some degree of hearing loss by 2050. Despite that scale, hearing loss remains chronically underaddressed. Traditional hearing aids are expensive, often requiring specialist fittings and follow-up appointments. For many people, that barrier is simply too high.

An FDA-cleared solution embedded in a consumer device changes the access equation significantly. Still, it is worth being clear about the limits: this is designed for perceived mild to moderate hearing loss, and Samsung is explicit that it is not a substitute for professional clinical care. Severe or profound hearing loss still requires specialist intervention.

But for the large group of people who have mild hearing difficulties and are doing nothing about it, this offers a practical, lower-cost entry point.

The context

Across the GCC, digital health is a policy priority. Saudi Arabia's Vision 2030 has made healthcare modernisation a central pillar, and the UAE has been actively investing in digital health infrastructure and telemedicine frameworks. In that context, FDA-cleared health features embedded in mainstream consumer devices are directly relevant to regional health strategies. They reduce the demand burden on specialist services and put diagnostic tools in the hands of individuals.

Samsung has been working toward this point since 2020, when it introduced a Personal Sound Amplification Product on the Galaxy Buds+. That was clinically validated in 2021 as effective support for daily communication among people with hearing loss. The FDA-cleared Hearing Aid feature is the result of six years of incremental development.

The feature will launch on Galaxy Buds3 Pro and Galaxy Buds4 Pro in the United States and select approved markets in Q4 2026. Regional availability will depend on local regulatory approvals, and GCC health authorities will need to assess the technology on their own terms before it reaches consumers here. But the direction of travel is clear.